Toll-like receptor 2

Toll-like receptor 2 also known as TLR2 is a protein that in humans is encoded by the TLR2 gene. TLR2 has also been designated as CD282 (cluster of differentiation 282). TLR2 is one of the toll-like receptors and plays a role in the immune system. TLR2 is a membrane protein, a receptor, which is expressed on the surface of certain cells and recognizes foreign substances and passes on appropriate signals to the cells of the immune system.

TLR2
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1FYW, 1FYX, 1O77, 2Z7X, 2Z80
Identifiers
Aliases	TLR2, CD282, TIL4, toll like receptor 2
External IDs	OMIM: 603028; MGI: 1346060; HomoloGene: 20695; GeneCards: TLR2; OMA:TLR2 - orthologs
Gene location (Human) Chr. Chromosome 4 (human) Band 4q31.3 Start 153,684,070 bp End 153,706,260 bp
Gene location (Mouse) Chr. Chromosome 3 (mouse) Band 3|3 E3 Start 83,743,579 bp End 83,749,074 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in monocyte blood granulocyte right lung upper lobe of left lung spleen bone marrow cartilage tissue bone marrow cells periodontal fiber Top expressed in granulocyte stroma of bone marrow right lung lobe tibiofemoral joint calvaria islet of Langerhans conjunctival fornix epithelium of lens cervix vestibular membrane of cochlear duct More reference expression data BioGPS More reference expression data
Gene ontology Molecular function pattern recognition receptor activity lipopolysaccharide binding Toll-like receptor binding triacyl lipopeptide binding protein binding peptidoglycan binding protein heterodimerization activity lipopolysaccharide immune receptor activity transmembrane signaling receptor activity lipopeptide binding Cellular component cytoplasm integral component of membrane phagocytic vesicle membrane Golgi apparatus membrane intrinsic component of plasma membrane plasma membrane Toll-like receptor 1-Toll-like receptor 2 protein complex integral component of plasma membrane membrane raft cytoplasmic vesicle cell projection cell surface cell body Biological process interleukin-10 production positive regulation of interferon-beta production defense response to Gram-positive bacterium positive regulation of interleukin-18 production positive regulation of toll-like receptor signaling pathway toll-like receptor TLR1:TLR2 signaling pathway positive regulation of inflammatory response cellular response to bacterial lipopeptide positive regulation of interleukin-12 production immune system process detection of diacyl bacterial lipopeptide cellular response to diacyl bacterial lipopeptide I-kappaB phosphorylation positive regulation of nitric-oxide synthase biosynthetic process MyD88-dependent toll-like receptor signaling pathway cellular response to triacyl bacterial lipopeptide detection of triacyl bacterial lipopeptide positive regulation of Wnt signaling pathway positive regulation of gene expression cellular response to lipoteichoic acid positive regulation of NF-kappaB transcription factor activity immune response positive regulation of interleukin-8 production positive regulation of interleukin-6 production positive regulation of tumor necrosis factor production positive regulation of chemokine production innate immune response inflammatory response toll-like receptor TLR6:TLR2 signaling pathway response to molecule of bacterial origin signal transduction positive regulation of transcription by RNA polymerase II apoptotic process response to lipopolysaccharide response to progesterone toll-like receptor signaling pathway response to insulin central nervous system myelin formation nitric oxide metabolic process response to fatty acid leukotriene metabolic process toll-like receptor 2 signaling pathway positive regulation of oligodendrocyte differentiation response to bacterial lipoprotein negative regulation of cell population proliferation response to toxic substance response to hypoxia positive regulation of interleukin-10 production lipopolysaccharide-mediated signaling pathway microglial cell activation Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 7097 24088 Ensembl ENSG00000137462 ENSMUSG00000027995 UniProt O60603 Q9QUN7 RefSeq (mRNA) NM_003264 NM_001318787 NM_001318789 NM_001318790 NM_001318791 NM_001318793 NM_001318795 NM_001318796 NM_011905 RefSeq (protein) NP_001305716 NP_001305718 NP_001305719 NP_001305720 NP_001305722 NP_001305724 NP_001305725 NP_003255 NP_036035 Location (UCSC) Chr 4: 153.68 – 153.71 Mb Chr 3: 83.74 – 83.75 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Function

The protein encoded by this gene is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. This gene is expressed most abundantly in peripheral blood leukocytes, and mediates host response to Gram-positive bacteria and yeast via stimulation of NF-κB.

In the intestine, TLR2 regulates the expression of CYP1A1, which is a key enzyme in detoxication of carcinogenic polycyclic aromatic hydrocarbons such as benzo(a)pyrene.

Background

The immune system recognizes foreign pathogens and eliminates them. This occurs in several phases. In the early inflammation phase, the pathogens are recognized by antibodies that are already present (innate or acquired through prior infection; see also cross-reactivity). Immune-system components (e.g. complement) are bound to the antibodies and kept near, in reserve to disable them via phagocytosis by scavenger cells (e.g. macrophages). Dendritic cells are likewise capable of phagocytizing but do not do it for the purpose of direct pathogen elimination. Rather, they infiltrate the spleen and lymph nodes, and each presents components of an antigen there, as the result of which specific antibodies are formed that recognize precisely that antigen.

These newly formed antibodies would arrive too late in an acute infection, however, so what we think of as "immunology" constitutes only the second half of the process. Because this phase would always start too late to play an essential role in the defense process, a faster-acting principle is applied ahead of it, one that occurs only in forms of life that are phylogenetically more highly developed.

What are called pattern-recognition receptors come into play here. This refers to receptors that recognize the gross, primarily structural features of molecules not innate to the host organism. These include, for example, lipids with a totally different basic chemical structure. Such receptors are bound directly to cells of the immune system and cause immediate activation of their respective nonspecific immune cells.

A prime example of such a foreign ligand is bacterial endotoxin, whose effects have been known for generations. When it enters the bloodstream it causes systematic activation of the early-phase response, with all the side effects of septic shock. This is known in the laboratory as the Shwartzman phenomenon. The intended effect is to mobilize the organism for combat, so to speak, and eliminate most of the pathogens.

Mechanism

As a membrane surface receptor, TLR2 recognizes many bacterial, fungal, viral, and certain endogenous substances. In general, this results in the uptake (internalization, phagocytosis) of bound molecules by endosomes/phagosomes and in cellular activation; thus such elements of innate immunity as macrophages, PMNs and dendritic cells assume functions of nonspecific immune defense, B1a and MZ B cells form the first antibodies, and specific antibody formation gets started in the process. Cytokines participating in this include tumor necrosis factor-alpha (TNF-α) and various interleukins (IL-1α, IL-1β, IL-6, IL-8, IL-12). Before the TLRs were known, several of the substances mentioned were classified as modulins. Due to the cytokine pattern, which corresponds more closely to T_h1, an immune deviation is seen in this direction in most experimental models, away from T_h2 characteristics. Conjugates are being developed as vaccines or are already being used without a priori knowledge.

A peculiarity first recognized in 2006 is the expression of TLR2 on Tregs (a type of T cell), which experience both TCR-controlled proliferation and functional inactivation. This leads to disinhibition of the early inflammation phase and of specific antibody formation. Following a reduction in pathogen count, many pathogen-specific Tregs are present that, now without a TLR2 signal, become active and inhibit the specific and inflammatory immune reactions (see also TNF-β, IL-10). Older literature that ascribes a direct immunity-stimulating effect via TLR2 to a given molecule must be interpreted in light of the fact that the TLR2 knockouts employed typically have very few Tregs.

Functionally relevant polymorphisms are reported that cause functional impairment and thus, in general, reduced survival rates, in particular in infections/sepsis with Gram-positive bacteria.

Signal transduction is depicted under Toll-like receptor.

Expression

TLR2 is expressed on microglia, Schwann cells, monocytes, macrophages, dendritic cells, polymorphonuclear leukocytes (PMNs or PMLs), B cells (B1a, MZ B, B2), and T cells, including Tregs (CD4+CD25+ regulatory T cells). In some cases, it occurs in a heterodimer (combination molecule), e.g., paired with TLR-1 or TLR-6. TLR2 is also found in the epithelia of air passages, pulmonary alveoli, renal tubules, and the Bowman's capsules in renal corpuscles. TLR2 is also expressed by intestinal epithelial cells and subsets of lamina propria mononuclear cells in the gastrointestinal tract. In the skin, it is found on keratinocytes and sebaceous glands; spc1 is induced here, allowing a bactericidal sebum to be formed.

Cancer

TLR2 gene has been observed progressively downregulated in Human papillomavirus-positive neoplastic keratinocytes derived from uterine cervical preneoplastic lesions at different levels of malignancy. For this reason, TLR2 is likely to be associated with tumorigenesis and may be a potential prognostic marker for uterine cervical preneoplastic lesions progression.

Agonists

The following ligands have been reported to be agonists of the toll-like receptor 2:

Agonist	Organism
Lipoteichoic acid	Gram-positive bacteria
atypical LPS	Leptospirosis and Porphyromonas gingivalis
MALP-2 and MALP-404 (lipoproteins)	Mycoplasma
-	Chlamydophila pneumoniae
OspA	Borrelia burgdorferi (Lyme disease)
Porin	Neisseria meningitidis, Haemophilus influenzae
Antigen mixtures	Cutibacterium acnes
LcrV	Yersinia
Lipomannan	Mycobacterium: Mycobacterium tuberculosis
GPI anchor	Trypanosoma cruzi
Lysophosphatidylserine	Schistosoma mansoni
Lipophosphoglycan (LPG)	Leishmania major
Glycophosphatidylinositol (GPI)	Plasmodium falciparum
Zymosan (a beta-glucan)	Saccharomyces cerevisiae
-	Malassezia (commensal yeast)
Antigen mixtures	Aspergillus fumigatus, Candida albicans
hsp60, as peptide transporter and adjuvant for antigen presentation	-
Glycoprotein (gH/gL, gB)	Herpes simplex virus
-	Varicella zoster virus
-	Cytomegalovirus (CMV)
Hemagglutinin	Measles
Active hexose correlated compound (AHCC)	Shiitake

Interactions

Protein-protein interactions

TLR 2 has been shown to interact with TLR 1 and TOLLIP. It has been shown that TLR2 can interact with spike and E-protein of SARS-CoV-2. The result of these interactions can be the activation of the immune system.

Protein-ligand interactions

TLR2 resides on the plasma membrane where it responds to lipid-containing PAMPs such as lipoteichoic acid and di- and tri-acylated cysteine-containing lipopeptides. It does this by forming dimeric complexes with either TLR 1 or TLR6 on the plasma membrane. TLR2 interactions with malarial glycophosphatidylinositols of Plasmodium falciparum was shown and a detailed structure of TLR–GPI interactions was computationally predicted.

Gene polymorphisms

Various single nucleotide polymorphisms (SNPs) of the TLR2 have been identified and for some of them an association with faster progression and a more severe course of sepsis in critically ill patients was reported. No association with occurrence of severe staphylococcal infection was found. Moreover, a recent study reported rs111200466, a TLR2 promoter insertion/deletion polymorphism as a prognosis factor in HIV-1 disease progression. The authors showed a correlation of the polymorphism with a faster progression to the CD4+ < 200 cells/μL outcome for the deletion allele carriers.

Further reading

• Aderem A, Ulevitch RJ (August 2000). "Toll-like receptors in the induction of the innate immune response". Nature. 406 (6797): 782–787. Bibcode:2000Natur.406..782A. doi:10.1038/35021228. PMID 10963608. S2CID 4410405.
• Ey B, Eyking A, Klepak M, Salzman NH, Göthert JR, Rünzi M, et al. (June 2013). "Loss of TLR2 worsens spontaneous colitis in MDR1A deficiency through commensally induced pyroptosis". Journal of Immunology. 190 (11): 5676–5688. doi:10.4049/jimmunol.1201592. PMC 3659955. PMID 23636052.
• Muzio M, Polentarutti N, Bosisio D, Manoj Kumar PP, Mantovani A (October 2000). "Toll-like receptor family and signalling pathway". Biochemical Society Transactions. 28 (5): 563–566. doi:10.1042/bst0280563. PMID 11044375.
• Hallman M, Rämet M, Ezekowitz RA (September 2001). "Toll-like receptors as sensors of pathogens". Pediatric Research. 50 (3): 315–321. doi:10.1203/00006450-200109000-00004. PMID 11518816. S2CID 24420705.
• Dziarski R, Gupta D (2001). "Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes". Journal of Endotoxin Research. 6 (5): 401–405. doi:10.1177/09680519000060050101. PMID 11521063.
• Lien E, Ingalls RR (January 2002). "Toll-like receptors". Critical Care Medicine. 30 (1 Suppl): S1-11. doi:10.1097/00003246-200201001-00001. PMID 11782555.
• Lorenz E (2007). "TLR2 and TLR4 expression during bacterial infections". Current Pharmaceutical Design. 12 (32): 4185–4193. doi:10.2174/138161206778743547. PMID 17100621.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.